Arcus Biosciences
Develops small-molecule and antibody therapies for cancer and inflammatory diseases.
$29.21
After-hours close+0.02 (+0.07%)
At close$29.19(−4.58%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 100.53%Insiders 4.55%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 125.77M · Float 88.98M · 70.8% free float
Institutions13F, as of Jun 30, 2026
238 holders · 126.44M shares · 49 new positions · 138 increased · 61 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 31.42M | 24.99% | 0 | Aug 3, 2026 |
| BlackRock, Inc. | 16.42M | 13.05% | +1.19M | Aug 7, 2026 |
| State Street Corp | 6.03M | 4.79% | +616.6K | Aug 7, 2026 |
| Wellington Management Group LLP | 5.90M | 4.69% | −194.1K | Aug 14, 2026 |
| Suvretta Capital Management, LLC | 4.78M | 3.80% | −254.6K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 4.48M | 3.56% | +203.5K | Aug 13, 2026 |
| FMR LLC | 4.05M | 3.22% | +2.88M | Aug 13, 2026 |
| Vanguard Capital Management LLC | 3.89M | 3.09% | +31.6K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 24.70% | 31.42M | 13D | Aug 7, 2026 ↗ |
| BlackRock, Inc. | 10.40% | 12.74M | 13G | Jan 8, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Terry J. Rosen | director, officer: Chief Executive Officer | 3.58M | 2.85% | Jan 26, 2026 |
| Juan C. Jaen | officer: President | 1.20M | 0.95% | Jul 13, 2026 |
| Jennifer Jarrett | officer: Chief Operating Officer | 224.0K | 0.18% | Jan 26, 2026 |
| Carolyn C. Tang | officer: General Counsel | 184.6K | 0.15% | Jun 12, 2026 |
| Richard Markus | officer: Chief Medical Officer | 89.6K | 0.07% | Jan 26, 2026 |
| II Robert C. Goeltz | officer: Chief Financial Officer | 84.2K | 0.07% | May 12, 2026 |
| David L. Lacey | director | 76.7K | 0.06% | Jun 12, 2026 |
| Andrew J. Perlman | director | 48.3K | 0.04% | Jun 12, 2026 |
| Kathryn E. Falberg | director | 44.3K | 0.04% | Jun 12, 2026 |
| Patrick Machado | director | 44.3K | 0.04% | Jun 12, 2026 |
3 ten-percent owners hold 33.39M shares by Form 4, outside the officers-and-directors figure above · 8 people have not refiled in the last 18 months (5.27M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Alexander Azoyofficer: Chief Accounting Officer | Sale | 2,827 | $30.00 | 39,581 |
| Jul 10, 2026 | Juan C. Jaenofficer: President | Sale · 2 lots | 20,067 | $28.62 | 822,240 |
| Jul 9, 2026 | Juan C. Jaenofficer: President | Sale | 48,502 | $30.05 | 842,307 |
| Jun 24, 2026 | Juan C. Jaenofficer: President | Sale | 6,431 | $29.66 | 890,809 |
| Jun 23, 2026 | Juan C. Jaenofficer: President | Sale · 2 lots | 15,764 | $27.73 | 897,240 |
| Jun 22, 2026 | Juan C. Jaenofficer: President | Sale | 9,236 | $27.03 | 913,004 |
| Jun 1, 2026 | Alexander Azoyofficer: Chief Accounting Officer | Sale | 2,562 | $25.77 | 39,581 |
| May 11, 2026 | II Robert C. Goeltzofficer: Chief Financial Officer | Sale | 7,763 | $25.63 | 84,161 |
| Jan 5, 2026 | Juan C. Jaenofficer: President | Sale · 3 lots | 31,823 | $21.41 | 922,240 |
| Dec 31, 2025 | II Robert C. Goeltzofficer: Chief Financial Officer | Sale | 6,552 | $23.38 | 67,924 |
CongressHouse and Senate disclosures
Not reported.